FDA notified healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. In April 2005, FDA notified healthcare professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Since issuing that notification, FDA has reviewed additional information that indicates the risk is also associated with conventional antipsychotics. Antipsychotics are not indicated for the treatment of dementia-related psychosis. The prescribing information for all antipsychotic drugs will now include the same information about this risk in a BOXED WARNING and the WARNINGS section.
Source: http://www.fda.gov/cder/drug/InfoSheets/HCP/antipsychotics_conventional.htm
Showing posts with label Antipsychotics. Show all posts
Showing posts with label Antipsychotics. Show all posts
Saturday, July 5, 2008
Friday, January 4, 2008
Clozapine-induced double incontinence
A case of clozapine-induced double incontinence in a 23 years old male diagnosed with schizophrenia and started on clozapine 25 mg/day has been reported in the latest isuue of Indian Journal of Medical Sciences.
On the Naranjo probability scale, the adverse drug reaction probability score for this patient to develop clozapine-induced double incontinence was nine, suggesting a definitive adverse reaction due to clozapine.
Source: Indian J Med Sci 2007;61:665-6
http://www.indianjmedsci.org/article.asp?issn=0019-5359;year=2007;volume=61;issue=12;spage=665;epage=666;aulast=Mendhekar
On the Naranjo probability scale, the adverse drug reaction probability score for this patient to develop clozapine-induced double incontinence was nine, suggesting a definitive adverse reaction due to clozapine.
Source: Indian J Med Sci 2007;61:665-6
http://www.indianjmedsci.org/article.asp?issn=0019-5359;year=2007;volume=61;issue=12;spage=665;epage=666;aulast=Mendhekar
Thursday, August 16, 2007
Risperidone- and Quetiapine-Induced Cholestasis
The Annals of Pharmacotherapy describes a case of a patient who developed drug-induced cholestasis after being on risperidone maintenance therapy for 8 years.
A 30-year-old male with schizoaffective disorder, bipolar type, and insulin-dependent diabetes mellitus had been stable on risperidone 6 mg at night for 8 years. His other medications included lithium 900 mg twice daily and enalapril 5 mg daily, as well as regular insulin and NPH insulin as needed. The patient developed cholestasis that resolved once risperidone was discontinued. Over the next 11 months, he tolerated trials of ziprasidone and olanzapine. When quetiapine was initiated, the patient developed signs and symptoms of cholestasis within 3 weeks after starting this medication. The signs and symptoms of cholestasis resolved with removal of quetiapine. The Naranjo probability scale indicated that these atypical antipsychotics (risperidone and quetiapine) were the probable cause of cholestasis in this patient.
Source: Annals of Pharmacotherapy 2007;41(9):1518-1523.
http://www.theannals.com/cgi/content/abstract/41/9/1518
A 30-year-old male with schizoaffective disorder, bipolar type, and insulin-dependent diabetes mellitus had been stable on risperidone 6 mg at night for 8 years. His other medications included lithium 900 mg twice daily and enalapril 5 mg daily, as well as regular insulin and NPH insulin as needed. The patient developed cholestasis that resolved once risperidone was discontinued. Over the next 11 months, he tolerated trials of ziprasidone and olanzapine. When quetiapine was initiated, the patient developed signs and symptoms of cholestasis within 3 weeks after starting this medication. The signs and symptoms of cholestasis resolved with removal of quetiapine. The Naranjo probability scale indicated that these atypical antipsychotics (risperidone and quetiapine) were the probable cause of cholestasis in this patient.
Source: Annals of Pharmacotherapy 2007;41(9):1518-1523.
http://www.theannals.com/cgi/content/abstract/41/9/1518
Subscribe to:
Posts (Atom)
